The Value of Tranexamic Acid in Reducing Blood Loss following Hip Reconstruction in Children with Cerebral Palsy
Table 2
Baseline characteristics of the study population.
Characteristics
No Tranexamic acid
Tranexamic acid
value
Number
37
14
Age (y)
10.2 (SD 3.3)
9.8 (SD 3.3)
0.74
Male (%)
21 (57%)
5 (36%)
0.22
Weight (kg)
30.2 (SD 11.8)
27.7 (SD 13.0)
0.54
GMFCS (low/high)
9/27
3/11
0.79
ASA (1/2/3/4/5)
3/18/8/0/0
1/6/5/0/0
0.32
Bilateral
10 (27%)
8 (57%)
0.06
Types of bony osteotomy (F, P, and B)
11/1/25
3/0/11
0.62
Prescribed NSAID (%)
19 (58%)
6 (50%)
0.74
Epilim (%)
5 (14%)
5 (36%)
0.12
Preoperative Hb (g/dL)
13.5 (SD 1.2)
13.3 (SD 1.4)
0.73
Preoperative Hct
0.397 (SD 0.032)
0.383 (SD 0.033)
0.19
GMFCS: gross motor function classification system, ASA: American Society of Anaesthetists, F: femoral osteotomy, P: pelvic osteotomy, B: both femoral and pelvic osteotomy, NSAID: nonsteroidal anti-inflammatory, Hb: hemoglobin, Hct: hematocrit, and SD: standard deviation.
